Chinese Hepatology 

About: Chinese Hepatology is an academic journal. The journal publishes majorly in the area(s): Lamivudine & Fatty liver. Over the lifetime, 65 publications have been published receiving 114 citations.

Study on the association of human XRCC_1-399 single nucleotide polymorphism and primary hepatocytic carcinoma

Abstract: Objective To investigate the correlation between a single nucleotide polymorphism (SNP) of XRCC_1-399, a human NDA repair gene, and the development of primary hepatocytic carcinoma (HCC) in a case-control study.Methods The XRCC_1-399 SNP was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 72 HCC patients with pathological evidences and 137 matched control subjects recruited by matching on living area, sex and age.Results (1) The XRCC_1-399 SNP and age were not associated with the HCC development. Among individuals with XRCC_1-399 Arg/Arg, the HCC development had an inverse correlation with age (P=(0.028)); (2) HBV infection was an overwhelming risk for the development of HCC (P=(0.007)). Of individuals with -399Gln/Gln or Arg/Gln, those with HBV infection had a greater risk than those without it ((25.7%) v.s. (5.3%), P=(0.047)). (3) The rates of HBV infection in subjects with XRCC_1-399 Arg/Arg and with -399Gln/Gln or Arg/Gln were similar ((36.6%) v.s. (38.0%), P=(0.052)).Conclusion (1) The allele of XRCC_1-399 Arg/Arg might potentially resist against HCC development. (2) The alleles of -399Gln/Gln or Arg/Gln paralleled with HBV infection had high risk for HCC development.

Polyunsaturated phosphatidylcholine (Essentiale) for alcoholic/fatty liver:A systematic review

Abstract: Objective To evaluate the efficacy and safety of Polyunsaturated phosphatidylcholine (PPC) for alcoholic/fatty liver Methods Randomized controlled trials comparing PPC versus placebo/no treatment for alcoholic/fatty liver were identified by electronic and manual searches No blinding、language and publishing were applied The methodological quality of trials was assessed in four aspect: generation of the allocation sequence、allocation concealment、blinding and follow-up Two reviewers independently assessed the methodological quality and extracted data on patients、methods、interventions and outcomes All the data was analyzed by the software of RevMan 42 supplied by the Cochrane CollaborationResults Six trials involving 662 patients were included The methodological quality was high in six randomized controlled trials No serious adverse events were reported One study involving 102 patients concerned for mortality The results indicated that PPC can reduce the early mortality ((226%) vs (392%), relative risk, RR (050), 95% confidence interval, CI(032)～(106),P=(0007)) Four studies involving 146 patients concerned for efficacy The combined results showed that PPC had positive effect on alcoholic/fatty liver((835%) vs (417%), RR(220); 95% CI(108)～(450)) Three articles including 546 patients reported the result of biopsy The combined results showed that the drug had no effect on histology improving But the drug has the trend for preventing histology warnseningConclusion PPC treatment is effective for alcoholic/fatty liver and improve the clinic symptoms and singns It has the positive tendency of reducing mortality and prevent histology worsening for alcoholic /fatty liver

Clinical features of drug-induced liver injury:A review of Chinese literatures 2003—2007

Abstract: Objective To analyse the overall clinical features of drug-induced liver injury from Chinese literatures published during the past five years.Methods Using drug-induced liver injury as key words, cases-analyze literatures on drug-induced liver injury from 2003 to 2007 in Chinese Periodical Full-text Database were searched, downloaded and recorded gender, age, drugs characters, clinical classifications and prognosis data. Results Among the recorded information, there were 7 465 (57.8%) male and 5 450(42.2%) female, the ratio of male to female is 1.37∶1. Age ranged from 3 months to 92 years old with the average 46.1 years. Drugs of antituberculotics, Chinese herbs, antibiotics, anti-hyperthyroidism drugs and antineoplastics were 5 484(43.78%), 2 026(16.17%), 1 579 (12.60%), 702(5.60%) and 640(5.11%) patients respectively. 2 510(62.73%)cases were classified to hepatocellular type, 830(20.74%) cases were cholestasis type and 661(16.52%) cases were mixed type. As the prognosis, 8 654(92.80%)cases cured or improve well , 239(2.56%) cases no change, 131(1.40%)cases became worse and 299(3.21%) cases dead.Conclusion It is reported in China that drug-induced liver injury occured more frequent in male; Antituberculotics, chinese herbs, antibiotics, anti-hyperthyroidism drugs, and antineoplastics were the five most common of drugs, most patients were hepatocellular and in general the prognosis is good.

Economic evaluation of peginterferon Alfa-2a and lamivudine in the treatment of HBeAg-negative chronic hepatitis B

Abstract: Objective To assess the long-term cost-effectiveness of peginterferon Alfa-2a and lamivudine in the treatment of HBeAg-negative chronic hepatitis B.Methods A Markov model was employed to conduct the economic evaluation based on the data retrieved from literatures and verified through Delphi method.Results Compared with one-year lamivudine treatment,one-year peginterferon Alfa-2a treatment can prolong 0.93 year for every HBeAg-negative CHB patient and the incremental medical cost was 16,675 RMB per life-year saved.Conclusion Peginterferon Alfa-2a is more cost effective than lamivudine in the treatment of HBeAg-negative chronic hepatitis B.

The development of cirrhosis in Chinese patients with chronic hepatitis B

Abstract: Objective To determine the incidence and the risk factors of liver cirrhosis in chronic hepatitis(CHB), including HBeAg-positive and HBeAg-negative CHB, and to explore the relationship between the hepatic pathology and the compensated or decompensated cirrhosis development in CHB. Methods The incidence and contributing factors of compensated or decompensated cirrhosis developing in CHB are assessed in 382 patients with clinicopathological evidence, including 262 cases of HBeAg-positive CHB and 120 cases of HBeAg-negative CHB. Cox regression was used to determine prognostic risk factors associated with compensated and decompensated cirrhosis.Results After the follow-up period of an average of 88.64 weeks, 75 cases (19.6%) occured compensated cirrhosis with an annual occurrence rate of 0.95%. 32 cases (8.4%) progressed to decompensated cirrhosis with an annual occurrence rate of 0.39%. The annual occurrence rates for compensated and decompensated cirrhosis in 262 cases of HBeAg-positive CHB are 0.84% (48 cases) and 0.32% (18 cases), respectively. These rates in 120 cases of HBeAg-negative CHB are 1.01% (27 cases) and 0.54% (14 cases), respectively. There is no statistical difference of cirrhosis between HBeAg-positive CHB and HBeAg-negative CHB. Risk for compensated and decompensated cirrhosis increases with the stage in CHB (P0.01, HR: 2.14 and 1.70) but not with the grade.Conclusion The present study suggests that compensated cirrhosis will develop in patients with CHB at an annual rate of 0.90% , and decompensated cirrhosis will develop in patients with CHB at an annual rate of 0.39%. There is no statistical difference of cirrhosis between HBeAg-positive CHB and HBeAg-negative CHB. The severity of the fibrosis stage at presentation is closely related with the development of compensated and decompensated cirrhosis development in CHB.